exatecan mesylate

Phase 2Completed

0 watching 0 views this week⚡ Active

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Fallopian Tube Cancer

Conditions

Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer

Trial Timeline

Jul 1, 1999 → Sep 1, 2000

NCT ID

NCT00004060

About exatecan mesylate

exatecan mesylate is a phase 2 stage product being developed by Daiichi Sankyo for Fallopian Tube Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT00004060. Target conditions include Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (11)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00055952	Phase 2	Completed	Jan 1, 2003	Apr 1, 2006	Sarcoma
NCT00055939	Phase 2	Completed	Jan 1, 2003	Apr 1, 2006	Sarcoma
NCT00017212	Phase 2	Completed	Apr 1, 2001	Sep 1, 2003	Esophageal Cancer
NCT00005938	Phase 2	Completed	Mar 1, 2000	Apr 1, 2005	Extrahepatic Bile Duct Cancer
NCT00004866	Phase 2	Completed	Jan 1, 2000	Sep 1, 2003	Cervical Cancer
NCT00004108	Phase 2	Completed	Sep 1, 1999	Apr 1, 2005	Liver Cancer
NCT00004060	Phase 2	Completed	Jul 1, 1999	Sep 1, 2000	Fallopian Tube Cancer
NCT00004046	Phase 2	Completed	Jun 1, 1999	Apr 1, 2002	Breast Cancer
NCT00003951	Phase 2	Completed	Jun 1, 1999	Apr 1, 2005	Pancreatic Cancer
NCT00004045	Phase 2	Completed	Jun 1, 1999	Aug 1, 2001	Prostate Cancer
NCT00004047	Phase 1	Completed	Jun 1, 1999	Apr 1, 2005	Leukemia

Competing Products

20 competing products in Fallopian Tube Cancer

See all competitors

Product	Company	Stage	Hype Score
PRGN-3005 UltraCAR-T cells + PRGN-3005 UltraCAR-T cells	Precigen	Phase 1	28
azenosertib	Zentalis Pharmaceuticals	Phase 2	44
Lenvatinib Mesylate + Paclitaxel	Eisai	Phase 1	33
decitabine + NY-ESO-1 peptide vaccine + pegylated liposomal doxorubicin hydrochloride + sargramostim + incomplete Freund's adjuvant	Eisai	Phase 1	33
ABT-767	AbbVie	Phase 1	33
Batiraxcept + Durvalumab	AstraZeneca	Phase 1/2	41
Carboplatin + Cediranib Maleate + Gemcitabine + Gemcitabine Hydrochloride + Olaparib + Paclitaxel + Pegylated Liposomal Doxorubicin Hydrochloride	AstraZeneca	Phase 3	77
Adavosertib + Paclitaxel + Carboplatin + Gemcitabine + PLD	AstraZeneca	Phase 2	52
plevitrexed + topotecan hydrochloride	AstraZeneca	Phase 2	52
Entinostat + Olaparib	AstraZeneca	Phase 1	33
AZD5335 + Itraconazole	AstraZeneca	Phase 1	33
Pembrolizumab	Merck	Phase 2	52
Carboplatin + Pembrolizumab	Merck	Phase 1/2	41
Guadecitabine + Pembrolizumab	Merck	Phase 2	52
recombinant adenovirus-p53 SCH-58500	Merck	Phase 1	33
Pembrolizumab + Paclitaxel + Carboplatin	Merck	Phase 2	52
AMG386 plus PLD + Placebo plus PLD	Amgen	Phase 3	76
AMG 386 + Paclitaxel + AMG 386 Placebo + Carboplatin	Amgen	Phase 3	76
AMG 386 + AMG 386 Placebo + Paclitaxel + Paclitaxel	Amgen	Phase 3	76
PF-06873600 + Endocrine Therapy 1 + Endocrine Therapy 2	Pfizer	Phase 1/2	40

Other Products from Daiichi Sankyo

Olmesartan medoxomil + Olmesartan medoxomil/hydrochlorothiazide + HydrochlorothiazideApproved

OAC aloneApproved

olmesartan medoxomil + Placebo + losartan potassiumApproved

Prasugrel + ClopidogrelApproved

Diet+pravastatinApproved